1 / 4

Pulmonary Arterial Hypertension Drug Pipeline Analysis

The Pulmonary Arterial Hypertension Market is Forecast to Show a High Growth Rate to 2015, but will Diminish in 2016

rgunnam
Download Presentation

Pulmonary Arterial Hypertension Drug Pipeline Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016

  2. The Pulmonary Arterial Hypertension Market is Forecast to Show a High Growth Rate to 2015, but will Diminish in 2016 GlobalData has estimated the global Pulmonary Arterial Hypertension (PAH) market to have been worth $2,653m in 2009. According to the Venice 2003 revised classification system, PAH is categorized as World Health Organization (WHO) Group I - PAH. Prior to 2001, no effective drug was approved for the treatment of PAH. Only supportive care medication such as anticoagulants, diuretics, oxygen, digoxin and calcium channel blockers were given to the patients. In 2001, the Food and Drug Administration (FDA) approved Tracleer as the treatment for patients with PAH. This drug was a registered trademark of Actelion Ltd. The sales of Tracleer grew rapidly due to a high patient switch over rate. The drug had a better efficacy and safety profile compared to the previously used off-label drugs. The FDA also approved three more drugs, Remodulin, Ventavis, and Revatio in 2002, 2004, and 2005 respectively for the treatment of PAH. However, these three drugs accounted for only a 24% market share to 2005. Between 2005 and 2009, the PAH market grew at a Compound Annual Growth Rate (CAGR) of 39.2% and recorded revenues of $2,653m in 2009. According to GlobalData’s analysis, the PAH market is forecast to increase at a CAGR of 5% annually over the next six years to reach $3,569m by 2015. Tracleer, the major revenue generator of the PAH market is due to go off patent by November 2015. The patent expiry of this drug is expected to diminish the market in 2016 by 25% to 27%. Until this time, the growth of the PAH market is primarily attributed to increased competition among existing products, the release of new and enhanced treatment options, and the development of safer and more efficacious therapies. The PAH market growth will be further supported by the increased uptake of promising molecules in the pipeline, combination therapies such as epoprostenol plus bosentan and epoprostenol plus sildenafil. In 2009, Actelion Ltd, with its key drug Tracleer, was the leading player in the global PAH market. For further details, please click or add this link to your browser: http://www.global-market-research-data.com/Report.aspx?ID=Pulmonary-Arterial-Hypertension-PAH-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

  3. Competition in the Pulmonary Arterial Hypertension Market is Expected to Intensify The leading companies in the global PAH market are Actelion Ltd., Eli Lilly & Co., Gilead Sciences, Inc., United Therapeutics Corporation, Pfizer, Inc., Genentech, Inc. (Roche), Bayer Schering Pharma AG, and Quadrant Technologies Limited. Together these companies accounted for more than 99% of the global PAH market in 2009. Actelion Ltd, with its blockbuster drug Tracleer, was the market leader with a share of more than 50% followed by Revatio and Remodulin with 15% each. However, companies such as Actelion Ltd., United Therapeutics Corporation, Bayer AG, Gilead Sciences, Pfizer Inc., Novartis AG, Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company, Lung RX, GlaxoSmithKline plc., and Cogentus Pharmaceuticals have the most technologically advanced products in their pipeline portfolios and are expected to attract the most investor attention. The global PAH market has seen some intense competition in recent times, which is expected to further intensify in the coming years. For further details, please click or add this link to your browser: http://www.global-market-research-data.com/Report.aspx?ID=Pulmonary-Arterial-Hypertension-PAH-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016 GlobalData, the industry analysis specialist’s new report, “Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016", is an essential source of information and analysis on the global PAH market. The report identifies the key trends shaping and driving the global PAH market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global PAH sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

  4. For further details, please click or add this link to your browser: http://www.global-market-research-data.com/Report.aspx?ID=Pulmonary-Arterial-Hypertension-PAH-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016 Or visit our report store: http://www.globaldata.com/reportstore Contact Information: Rajesh Gunnam rgunnam@globaldata.com +914066166782

More Related